OCON Therapeutics, a pioneer recognized by the World Economic Forum for its advancements in drug delivery, has announced a significant milestone with the completion of a $10 million investment round led by RH Capital. This funding marks a pivotal moment for OCON as it accelerates efforts to redefine the standard of care in women’s health through its innovative 3D drug delivery system.
OCON Therapeutics remains at the forefront of developing revolutionary drug delivery solutions aimed at addressing prevalent uterine pathologies. Central to its mission is the utilization of its proprietary IUB® (Intra-Uterine Ball) platform, exemplified by products such as IUB SEAD® and IUB PRIMA®, designed to combat conditions like abnormal and heavy uterine bleeding. These conditions affect a substantial portion of the global population, underscoring the critical need for effective and tailored treatments.
The investment round, which secured $10 million, was led by RH Capital and saw participation from Features Capital, Astia Angels, Exerte Partners, and grants from the Israeli Innovation Authority, among others. This infusion of capital will enable OCON to expand its clinical programs, advance regulatory approvals, and broaden its product portfolio. Notably, OCON’s commitment extends beyond innovation to include enhancing health outcomes and quality of life for women worldwide, addressing a market opportunity estimated at $35 billion.
Keren Leshem, CEO of OCON Therapeutics, emphasized the company’s dedication to offering safer and more innovative healthcare options for women. She highlighted, “Our technology aims to provide physicians and patients with advanced, targeted treatments that minimize risks associated with traditional approaches, such as surgeries or systemic medications. This funding round is a testament to our investors’ confidence in our vision and capabilities.”
Jenny Barba, Co-Founder and Managing Partner of Features Capital, expressed confidence in OCON’s technological advancements, stating, “OCON’s IUB® platform represents a transformative approach to gynecological care, aligning with our mission to unlock breakthrough solutions that redefine patient outcomes and address global health challenges.”
Looking ahead, OCON is preparing to initiate pivotal studies in the USA for its IUB SEAD® product and is poised to advance its IUB PRIMA® for long-term reversible contraception and menstrual health. Moreover, the company plans to expand its product pipeline to include treatments for endometriosis and uterine fibroids, leveraging its innovative drug-releasing technology under the IUB STELLA™ and IUB ADIRA™ brands.
Editorial Opinion
OCON Therapeutics emerges as a beacon of innovation in the realm of women’s health, poised at the intersection of cutting-edge technology and compassionate care. With its revolutionary IUB® platform, the company not only addresses prevalent uterine pathologies but also sets a new standard for personalized healthcare solutions tailored to the unique needs of women worldwide. The recent $10 million investment underscores not just financial backing but a resounding vote of confidence in OCON’s vision and capabilities. By focusing on advancing treatments like IUB SEAD® and IUB PRIMA®, which offer both hormonal and non-hormonal options for conditions affecting millions of women globally, OCON is not only enhancing therapeutic outcomes but also paving the way for safer, more effective treatments that minimize side effects and improve patient compliance. This strategic direction, coupled with expanding clinical trials and regulatory approvals, positions OCON at the forefront of the industry, poised to unlock significant value in a market ripe with opportunity. As the company prepares to broaden its portfolio to include solutions for endometriosis and uterine fibroids through IUB STELLA™ and IUB ADIRA™, it reaffirms its commitment to driving meaningful change in women’s healthcare, promising a future where advanced technology meets compassionate care to empower women to live healthier, more fulfilling lives. OCON Therapeutics is not just revolutionizing treatment paradigms; it is shaping the future of women’s health with innovation, integrity, and a steadfast dedication to improving the lives of women everywhere.
